Amphivena Therapeutics

Amphivena Therapeutics, Inc. is a privately held clinical-stage immuno-oncology company developing a novel bispecific biologics platform that can alleviate immune suppression, drive T-cell activation and polarization, to restore patients' anti-cancer immunity. The company’s lead product, AMV564, a bispecific antibody targeting CD33 and CD3, is currently in Phase 1 clinical trials for certain hematologic cancers as well as solid tumors.